Designing drugs against the fibroblast growth factor (FGF) pathway is complicated by the fact that there are several FGF family members with different biological activities. Blocking the hormonal FGFs causes toxicities; so, Harding et al. developed a soluble decoy receptor, FP-1039, that binds only the mitogenic FGFs. FP-1039 blocked FGF- and vascular endothelial growth factor (VEGF)-induced angiogenesis in vivo, and inhibited tumour growth in several xenograft mouse models with minimal toxicity. Xenografts of cancer cells with FGF pathway alterations were particularly sensitive to FP-1039.
ORIGINAL RESEARCH PAPER
Harding, T. C. et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci. Transl. Med. 5, 178ra39 (2013)
Rights and permissions
About this article
Cite this article
Seton-Rogers, S. Picking and choosing. Nat Rev Cancer 13, 295 (2013). https://doi.org/10.1038/nrc3522
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3522